Results 21 to 30 of about 2,051 (160)

Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma

International Journal of Nanomedicine, 2014
Ying Li,1,* Jiani Yuan,1,* Qian Yang,1 Wei Cao,1 Xuanxuan Zhou,1 Yanhua Xie,1 Honghai Tu,2 Ya Zhang,1 Siwang Wang1 1Department of Natural Medicine and Institute of Materia Medica, School of Pharmacy, Fourth Military Medical University, Xi’an ...
Li Y, Yuan J, Yang Q, Cao W, Zhou X, Xie Y, Tu H, Zhang Y, Wang S   +8 more
doaj   +1 more source

Bufalin Inhibits Cytokine Storm by Regulating TLR4/TLR3 Signaling Pathway. [PDF]

Immun Inflamm Dis
ABSTRACT Background Bufalin is one main component of the dried venom from Bufo gargarizans Cantor, which has anti‐tumor, cardiotonic, anti‐inflammatory and other physiological activities. However, in recent years, researchers have mainly paid attention to its anti‐tumor effect and neglected its anti‐inflammatory effect.
Liu X, Li C, Yang J, Zhang W, Hu Z, Zhang X, Jianati R, Tian F, Dai X, Xu Z, Chen B, Zhu X.   +11 more
europepmc   +2 more sources

Determination of Endogenous Bufalin in Serum of Patients With Hepatocellular Carcinoma Based on HPLC-MS/MS

Frontiers in Oncology, 2020
Bufalin is a cardiotonic steroid and a key active ingredient of the Chinese medicine ChanSu. It has significant anti-tumor activity against many malignancies, including hepatocellular carcinoma (HCC). Previous studies have shown that human bodies contain
Mengfei Han, Geliang Yang, Qing Lin, Yanlong Yang, Huiqing Zhang, Yonghua Su, Yonghua Su   +6 more
doaj   +1 more source

Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress. [PDF]

PLoS ONE, 2015
Sorafenib is the standard first-line therapeutic treatment for patients with advanced hepatocellular carcinoma (HCC), but its use is hampered by the development of drug resistance.
Bo Zhai, Fengli Hu, Haijiang Yan, Dali Zhao, Xin Jin, Taishi Fang, Shangha Pan, Xueying Sun, Lishan Xu   +8 more
doaj   +1 more source

Artificial intelligence empowers targeted protein degradation: Core technological innovations, multi-scenario applications, and translational prospects. [PDF]

Smart Mol
AI is transforming TPD by improving the design, prediction, and optimization of degraders such as PROTACs, molecular glues, and LYTACs. This review summarizes key AI‐driven advances, highlights applications across drug discovery stages, and discusses remaining challenges and future directions for accelerating the development of therapies against ...
Qin S, Peng R, Zhang G, Yan S, Xiao J, Liu Z, Tan Z, Xie Q, Li S, Luo W, Xiao X.   +10 more
europepmc   +2 more sources

Bufalin-Mediated Regulation of Cell Signaling Pathways in Different Cancers: Spotlight on JAK/STAT, Wnt/β-Catenin, mTOR, TRAIL/TRAIL-R, and Non-Coding RNAs

Molecules, 2023
The renaissance of research into natural products has unequivocally and paradigmatically shifted our knowledge about the significant role of natural products in cancer chemoprevention. Bufalin is a pharmacologically active molecule isolated from the skin
Ammad Ahmad Farooqi, Venera S. Rakhmetova, Gulnara Kapanova, Gulnara Tashenova, Aigul Tulebayeva, Aida Akhenbekova, Onlassyn Ibekenov, Assiya Turgambayeva, Baojun Xu   +8 more
doaj   +1 more source

Bufalin suppresses tumour microenvironment-mediated angiogenesis by inhibiting the STAT3 signalling pathway

Journal of Translational Medicine, 2021
Background Antiangiogenic therapy has increasingly become an important strategy for the treatment of colorectal cancer. Recent studies have shown that the tumour microenvironment (TME) promotes tumour angiogenesis.
Kai Fang, Yueping Zhan, Ruiqiu Zhu, Yuqian Wang, Chengqi Wu, Min Sun, Yanyan Qiu, Zeting Yuan, Xin Liang, Peihao Yin, Ke Xu   +10 more
doaj   +1 more source

Silencing c-Myc Enhances the Antitumor Activity of Bufalin by Suppressing the HIF-1α/SDF-1/CXCR4 Pathway in Pancreatic Cancer Cells

Frontiers in Pharmacology, 2020
BackgroundPancreatic cancer is one of the most aggressive malignancies. Bufalin, a traditional Chinese medicine, has been used to treat pancreatic cancer as an antitumor agent although the mechanism by which it exerts its effects is still unclear.
Xia Liu, Yayun Zhou, Yayun Zhou, Jiamin Peng, Bei Xie, Qiyang Shou, Jianchao Wang   +6 more
doaj   +1 more source

Degradation of Mcl-1 through GSK-3β Activation Regulates Apoptosis Induced by Bufalin in Non-Small Cell Lung Cancer H1975 Cells

Cellular Physiology and Biochemistry, 2017
Background/Aims: Mcl-1, an anti-apoptotic Bcl-2 family member, is often overexpressed in non-small cell lung cancer (NSCLC). Bufalin has been reported to induce apoptosis in various tumor cells.
Xiao-hong Kang, Jing-hang Zhang, Qing-qin Zhang, Yan-hui Cui, Ying Wang, Wei-zheng Kou, Zhan-hui Miao, Ping Lu, Li-Fang Wang, Zhen-ye Xu, Fei Cao   +10 more
doaj   +1 more source

An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives

Frontiers in Pharmacology, 2023
Profound progress has been made in cancer treatment in the past three decades. However, drug resistance remains prevalent and a critical challenge.
Qingmei Ye, Qingmei Ye, Xin Zhou, Han Ren, Fangxuan Han, Rong Lin, Juan Li   +6 more
doaj   +1 more source